Lilly’s weight loss pill shows 13% weight loss in adults over 65 years of age

Lilly’s weight loss pill gained approval in April 2026, around three months after Novo Nordisk gained the same accolade for oral Wegovy. Lilly’s weight loss pill gained approval in April 2026, around three months after Novo Nordisk gained the same accolade for oral Wegovy. Lilly debuted the data for Foundayo at ECO 2026. Credit: Michael Siluk/UCG/Universal Images Group via Getty Images Eli Lilly’s Foundayo (orforglipron) has led to weight loss of 13% in post-hoc analysis of patients aged over 65 from two Phase III trials. In data presented at the European Congress on Obesity (ECO) 2026 in Istanbul, Turkey, the…

Source: Clinical Trials Arena